Prevalence estimates of diagnosed viral hepatitis B, liver condition outcomes and hospitalization costs

a population record-linkage study in Tayside, Scotland

D J McLernon, P T Donnan, J F Dillon

Research output: Contribution to journalArticle

4 Downloads (Pure)

Abstract

SUMMARY We estimated prevalence and incidence of liver condition outcomes, and costs to the health service of diagnosed hepatitis B virus (HBV) in Tayside, UK. HBV patients were identified from electronic virology data between 1989 and 2003. The health resource costs of HBV for surface antigen-positive (HBsAg+) patients and HBV (HBsAg+ or immune, i.e. recovered) patients were calculated. A total of 633 patients had HBV (275 HBsAg+), and were more likely to be male (62% vs. 48%), older (mean age 42·6 vs. 39·2 years) and deprived than the general population. The prevalence of immune individuals increased steadily. Post-HBV diagnosis, 24% of immune and 13% of HBsAg+ patients were diagnosed with a liver condition. The median cost per immune patient (£3023) was greater than per HBsAg+ patient (£1498) (P = 0·02). While increasing prevalence of immune HBV patients highlights an increase in screening and treatment, the costs associated with this group are high.
Original languageEnglish
Pages (from-to)2122-2130
Number of pages9
JournalEpidemiology and Infection
Volume141
Issue number10
Early online date3 Dec 2012
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Scotland
Hepatitis B
Hepatitis B virus
Hospitalization
Hepatitis B Surface Antigens
Costs and Cost Analysis
Liver
Population
Health Care Costs
Virology
Health Resources
Health Services
Incidence

Keywords

  • Hepatitis B

Cite this

@article{c8d9e419fbea4daa80bdeae136b812b8,
title = "Prevalence estimates of diagnosed viral hepatitis B, liver condition outcomes and hospitalization costs: a population record-linkage study in Tayside, Scotland",
abstract = "SUMMARY We estimated prevalence and incidence of liver condition outcomes, and costs to the health service of diagnosed hepatitis B virus (HBV) in Tayside, UK. HBV patients were identified from electronic virology data between 1989 and 2003. The health resource costs of HBV for surface antigen-positive (HBsAg+) patients and HBV (HBsAg+ or immune, i.e. recovered) patients were calculated. A total of 633 patients had HBV (275 HBsAg+), and were more likely to be male (62{\%} vs. 48{\%}), older (mean age 42·6 vs. 39·2 years) and deprived than the general population. The prevalence of immune individuals increased steadily. Post-HBV diagnosis, 24{\%} of immune and 13{\%} of HBsAg+ patients were diagnosed with a liver condition. The median cost per immune patient (£3023) was greater than per HBsAg+ patient (£1498) (P = 0·02). While increasing prevalence of immune HBV patients highlights an increase in screening and treatment, the costs associated with this group are high.",
keywords = "Hepatitis B",
author = "McLernon, {D J} and Donnan, {P T} and Dillon, {J F}",
year = "2013",
month = "10",
doi = "10.1017/S095026881200266X",
language = "English",
volume = "141",
pages = "2122--2130",
journal = "Epidemiology and Infection",
issn = "0950-2688",
publisher = "Cambridge University Press",
number = "10",

}

TY - JOUR

T1 - Prevalence estimates of diagnosed viral hepatitis B, liver condition outcomes and hospitalization costs

T2 - a population record-linkage study in Tayside, Scotland

AU - McLernon, D J

AU - Donnan, P T

AU - Dillon, J F

PY - 2013/10

Y1 - 2013/10

N2 - SUMMARY We estimated prevalence and incidence of liver condition outcomes, and costs to the health service of diagnosed hepatitis B virus (HBV) in Tayside, UK. HBV patients were identified from electronic virology data between 1989 and 2003. The health resource costs of HBV for surface antigen-positive (HBsAg+) patients and HBV (HBsAg+ or immune, i.e. recovered) patients were calculated. A total of 633 patients had HBV (275 HBsAg+), and were more likely to be male (62% vs. 48%), older (mean age 42·6 vs. 39·2 years) and deprived than the general population. The prevalence of immune individuals increased steadily. Post-HBV diagnosis, 24% of immune and 13% of HBsAg+ patients were diagnosed with a liver condition. The median cost per immune patient (£3023) was greater than per HBsAg+ patient (£1498) (P = 0·02). While increasing prevalence of immune HBV patients highlights an increase in screening and treatment, the costs associated with this group are high.

AB - SUMMARY We estimated prevalence and incidence of liver condition outcomes, and costs to the health service of diagnosed hepatitis B virus (HBV) in Tayside, UK. HBV patients were identified from electronic virology data between 1989 and 2003. The health resource costs of HBV for surface antigen-positive (HBsAg+) patients and HBV (HBsAg+ or immune, i.e. recovered) patients were calculated. A total of 633 patients had HBV (275 HBsAg+), and were more likely to be male (62% vs. 48%), older (mean age 42·6 vs. 39·2 years) and deprived than the general population. The prevalence of immune individuals increased steadily. Post-HBV diagnosis, 24% of immune and 13% of HBsAg+ patients were diagnosed with a liver condition. The median cost per immune patient (£3023) was greater than per HBsAg+ patient (£1498) (P = 0·02). While increasing prevalence of immune HBV patients highlights an increase in screening and treatment, the costs associated with this group are high.

KW - Hepatitis B

U2 - 10.1017/S095026881200266X

DO - 10.1017/S095026881200266X

M3 - Article

VL - 141

SP - 2122

EP - 2130

JO - Epidemiology and Infection

JF - Epidemiology and Infection

SN - 0950-2688

IS - 10

ER -